SEC Form 4 · accession 0001562180-17-001467
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Ron Squarer
Officer — CEO · Director
Period of report
Apr 1, 2017
Accepted (ET)
Apr 4, 2017 · 9:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Apr 1, 2017 | M | 18,906 | $0.00 | A | 126,369 | D | |
| Common StockF3 | Apr 1, 2017 | F | 12,042 | $8.94 | D | 114,327 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F4,F5 | $0.00 | Apr 1, 2017 | M | 18,906 | D | — | Apr 2, 2020 | Common Stock | 18,906 | 56,719 | D |
Explanation of responses
- F1Represents shares issued on settlement of Restricted Stock Units ("RSUs") granted to the reporting person, of which 6,047 shares were withheld upon vesting to satisfy tax withholding obligations.The grant of these RSUs was previously reported on Table II of a form 4 filed by the reporting person.
- F2Includes 37,813 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs, and 6,877 shares purchased pursuant to the issuer's Employee Stock Purchase Plan on December 31, 2016.
- F3Represents shares withheld to satisfy tax withholding obligations of the reporting person in connection with the vesting of RSUs held by the reporting person.
- F4The RSUs vest and will be settled in stock in four equal annual installments beginning April 1, 2017.
- F5Consists of unvested RSUs awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs was previously reported on Table II of a form 4 filed by the reporting person.